老虎證券

BUZZ-Outlook Therapeutics plunges after FDA rejects eye drug for third time

Reuters
01/02
BUZZ-Outlook <a href="https://laohu8.com/S/LENZ">Therapeutics</a> plunges after FDA rejects eye drug for third time

** Shares of Outlook Therapeutics OTLK.O plunge 59.6% to 64 cents premarket

** U.S. FDA declines to approve co's Lytenava for wet age-related macular degeneration, citing lack of confirmatory evidence of efficacy

** Decision marks third rejection after earlier refusals in 2023 and Aug 2025

** Lytenava, an eye disease-specific adaptation of bevacizumab, failed to match Roche's ROG.S Lucentis in key trial

** Drug already approved in EU and UK; FDA has not indicated what type of confirmatory evidence would be acceptable

** OTLK down 16.4% in 2025

(Reporting by Tharuniyaa Lakshmi in Bengaluru)

((tharuniyaa@thomsonreuters.com))

應版權方要求，你需要登入查看該內容

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10